Get the Stockscreener App
1.03
2.83%
-0.03
After Hours:
1.00
-0.03
-2.91%
Cytosorbents Corp Stock (CTSO) Latest News
Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com - Defense World
Cytosorbents (NASDAQ:CTSO) Earns “Buy” Rating from D. Boral Capital - Defense World
When Will CytoSorbents Release Q4 2024 Results? Key Date for Investors - StockTitan
CytoSorbents secures $1.6 million from warrant exercises - Investing.com
CytoSorbents Secures $1.6M Capital InjectionWill This Fuel Their FDA Application Success? - StockTitan
StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO) - Defense World
Cytosorbents Co. (NASDAQ:CTSO) Sees Significant Increase in Short Interest - Defense World
B. Riley Securities initates Cytosorbents Corp (CTSO) rating to a Buy - Knox Daily
CTSO stock touches 52-week high at $1.6 amid robust annual growth - MSN
Cytosorbents (NASDAQ:CTSO) Stock Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Cytosorbents (NASDAQ:CTSO) Stock Passes Above Two Hundred Day Moving Average – Should You Sell? - Defense World
Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com - Defense World
Sargent Investment Group LLC Sells 377,384 Shares of Cytosorbents Co. (NASDAQ:CTSO) - MarketBeat
Cytosorbents (NASDAQ:CTSO) Stock Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Vanguard Group Inc's Strategic Acquisition of CytoSorbents Corp Shares - GuruFocus.com
Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com - Defense World
Chief Medical Officer Deliargyris Efthymios exercised 16,233 in-the-money shares at a strike of $1.00, increasing direct ownership by 4% to 403,025 units (SEC Form 4) - Quantisnow
CytoSorbents Strengthens Balance Sheet with Successful Conclusion of Rights Offering - Defense World
Cytosorbents Boosts Liquidity with Successful Rights Offering - Yahoo Finance
Cytosorbents (NASDAQ:CTSO) Given Buy Rating at D. Boral Capital - Defense World
CytoSorbents closes oversubscribed rights offering - MSN
D. Boral Capital Reiterates Buy Rating for Cytosorbents (NASDAQ:CTSO) - MarketBeat
Expert Outlook: CytoSorbents Through The Eyes Of 7 Analysts - Benzinga
CytoSorbents Raises $6.25M in Oversubscribed Rights Offering, Unlocks $5M Restricted Cash - StockTitan
Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com - Defense World
Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com - MarketBeat
Cytosorbents Co. (NASDAQ:CTSO) Stake Boosted by Geode Capital Management LLC - Defense World
Skylands Capital, LLC Increases Stake in CytoSorbents Corp - GuruFocus.com
Revenue Surge & Breakthrough Margins Fuel Growth in Critical Care Tech - Streetwise Reports
CytoSorbents opens new sales subsidiary in Dubai - Investing.com
CytoSorbents Expands Global Reach with Strategic Dubai Hub for Middle East & Africa Growth - StockTitan
CytoSorbents reported strong Q4 results, says D. Boral Capital - Yahoo Finance
Health Care Equipment Supplier CytoSorbents Shares Dip Despite Projected Revenue Growth - Benzinga
Cytosorbents' (CTSO) Buy Rating Reiterated at D. Boral Capital - MarketBeat
CytoSorbents reports revenue growth in Q4 - Investing.com
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue - Quantisnow
CytoSorbents Delivers Strong Q4 Growth: Product Revenue Surges 25%, Margins Hit 70% Milestone - StockTitan
Comparing Cytosorbents (NASDAQ:CTSO) & Presbia (OTCMKTS:LENSF) - Defense World
CytoSorbents begins rights offering for stockholders - Investing.com
CytoSorbents Launches $1.00 Rights Offering with Discounted Warrant Package for Shareholders - StockTitan
StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO) - Defense World
Peter J. Mariani Purchases 20,000 Shares of Cytosorbents Co. (NASDAQ:CTSO) Stock - MarketBeat
Cytosorbents CFO Peter J. Mariani buys $19,294 in common stock - Investing.com India
1.02%
2.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):